Comparison of diurnal intraocular pressure control by latanoprost versus travoprost: Results of an observational survey

Clinical Drug Investigation

Volumn 26, Issue 12, 2006, Pages 703-714

  Denis, Philippe ^a   Launois, Robert ^b   Devaux, Marion ^b   Berdeaux, Gilles ^c,d,e  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Réseau d Evaluation en Economie de la Sante REES   (France)

^c Bioinformatique et Chimie Moléculaire   (France)

^d Alcon France ^*  (France)

^e Alcon France   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; PROSTAGLANDIN DERIVATIVE; TRAVOPROST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; CIRCADIAN RHYTHM; CLOPROSTENOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC;

EID: 33845451914     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626120-00004     Document Type: Article

References (31)

1. Enquête permanente de la prescription médicale. IMS Health, Puteaux, France
2. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472-84
3. Netland PA, Robertson SM, Sullivan EK, et al. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther 2003; 20: 149-63
4. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997; 41 Suppl. 2: S105-10
5. Cohen JS, Gross RL, Cheetham JK, et al. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004; 49 Suppl. 1: S45-52
6. Van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005; 112: 1177-85
7. Nordmann JP, Lafuma A, Pradet S, et al. Clinical outcomes of glaucoma treatments over a patient life: a Markov model. J Glaucoma 2005; 14 (6): 463-9
8. Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004; 26: 84-91
9. Walters TR, DuBiner HB, Carpenter SP, et al. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004; 49: 26-35
10. Roulland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review. Drugs Aging 2005; 22: 315-21
11. Bernstein PA. Comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol 2004; 137: 387-8
12. Noecker RS, Dirks MS, Choplin N. Comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2004; 137: 210-1
13. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135: 688-703
14. Nordmann JP, LePen C, Lilliu H, et al. Estimating the long-term visual field consequences of average daily intraocular pressure and variance: a clinical trial comparing timolol, latanoprost and travoprost. Clin Drug Invest 2003; 23: 431-8
15. Halpern MT, Covert DW, Robin AL. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects. Trans Am Ophthalmol Soc 2002; 100: 109-17
16. DuBiner H, Berdeaux G. Impact of daily IOP veriability on prescription decisions. Proceedings of International Symposium on Ocular Pharmacology and Therapeutics, 5th International Symposium, Bologna, Mar 2004. Bologna: Monduzzi Editore, 2004: pp. 207-9
17. Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004; 13: 283-90
18. Le Pen C, Ligier M, Berdeaux G. Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom. J Med Econ 2005; 8: 67-84
19. Jonsson B, Krieglstein G. Primary open-angle glaucoma: differences in international treatment patterns and costs. Oxford: Ed Isis Medical Media, 1999
20. Oostenbrink JB, Rutten-van Molken MP, Sluyter-Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in The Netherlands. J Glaucoma 2001; 10: 184-91
21. Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998; 7: 95-104
22. Hjelmgren J, Berggren F, Andersson D. Health economics guidelines: similarities, differences and some implications. Value Health 2001; 4: 225-50
23. Deschaseaux-Voinet C, Lafuma A, Berdeaux G. Cost and effectiveness of brinzolamide versus dorzolamide in current practice: an analysis based on the UK-GPRD data base. J Med Econ 2003; 6: 69-78
24. Reardon G, Schwartz GF, Mozaffari E. Patient persistence with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther 2003; 25: 1172-85
25. Reardon G, Schwartz GF, Mozaffari E. Patient persistence with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004; 137 (1 Suppl.): S3-12
26. Denis P, Lafuma A, Berdeaux G. Medical outcome of glaucoma therapy from a nationwide representative survey. Clin Drug Invest 2004; 24: 343-52
27. Rouland JF, LePen C. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. Eur J Ophthalmol 2003; 13 Suppl. 4: S5-20
28. Baudouin C, Rouland JF, LePen C. Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France. Eur J Ophthalmol 2003; 13 Suppl. 4: S53-60
29. Association des Epidemiologistes de Langue Française. Déontologie et bonnes pratiques en epidemiologie, recommandations de l'Association Des Epidémiologistes de Langue Française, Paris 1997
30. Newgard CD, Hedges HR, Arthur M, et al. Advanced statistics. The propensity score: a method for estimating treatment effect in observational research. Acad Emerg Med 2004; 11: 953-61
31. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-40